Agenus Inc. buy Robert W. Baird
Start price
05.06.23
/
50%
€1.68
Target price
05.06.24
-
Performance (%)
-76.79%
Price
11.04.24
€0.41
Summary
This prediction is currently active. Massive losses of -76.79% have been the result for the BUY prediction by Robert_W__Baird. This prediction currently runs until 05.06.24. The prediction end date can be changed by Robert_W__Baird at any time. Robert_W__Baird has 50% into this predictionAgenus is a biotechnology company focused on developing immunotherapies to treat cancer and other diseases. The company's product pipeline includes checkpoint inhibitors, which work by blocking proteins that help cancer cells evade detection by the immune system, as well as other immunotherapies designed to stimulate the body's immune response to tumors. Agenus has collaborations with large pharmaceutical companies including Merck, Incyte, and Gilead, and is actively working on bringing its products to market through clinical trials and regulatory approval. The company is listed on the NASDAQ stock exchange under the ticker symbol AGEN.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Agenus Inc. | - | - |
| iShares Core DAX® | -0.922% | -1.993% |
| iShares Nasdaq 100 | 0.371% | -0.868% |
| iShares Nikkei 225® | 2.224% | -5.187% |
| iShares S&P 500 | -0.026% | -0.918% |
Comments by Robert_W__Baird for this prediction
In the thread Agenus Inc. diskutieren
Agenus Inc. (NASDAQ: AGEN) is now covered by analysts at Robert W. Baird. They set an "outperform" rating on the stock.
Ratings data for AGEN provided by MarketBeat